Oxford Ovarian Cancer Predict Chemotherapy Response 01 (OXO-PCR-01)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01770535
Verified January 2013 by University of Oxford. Recruitment status was: Recruiting
The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.
Condition or disease
While paclitaxel is very effective in killing cancer cells in a proportion of patients, some patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated with unpleasant side effects. We are doing this study to try and understand what is happening in cancer cells in different individuals after paclitaxel treatment that make them respond differently to the same treatment. We hope that this study will enable us to develop a method to identify women who are suitable for this form of treatment. We also want to understand why some cancer cells don't get killed with paclitaxel. This information will help us to select treatment to suit an individual patient, and thus improve the outcome of treatment and avoid giving treatment that will not benefit the patient.
Correlation between βIII tubulin expression and Mitotic Index (MI) following single agent paclitaxel treatment [ Time Frame: Before and 24-hours after paclitaxel treatment ]
Correlation between βIII tubulin expression and Mitotic Index (MI) before and after single agent paclitaxel treatment to determine whether overexpression of βIII tubulin is associated with Paclitaxel resistance
Secondary Outcome Measures
Correlation between mitotic index and the magnitude of CA125 response [ Time Frame: three weeks after paclitaxel treatment ]
Correlation between mitotic index and the magnitude of CA125 response will be analysed to investigate whether post-paclitaxel mitotic index is a determinant of clinical response in ovarian cancer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with radiological and histological evidence of advanced ovarian cancer, who would standardly be managed by primary chemotherapy and interval debulking surgery
Female ≥ 18 years of age
Newly diagnosed and histology confirmed primary high grade serous ovarian cancer, high grade serous fallopian tube cancer and primary peritoneal carcinoma.
Radiological and laparoscopic confirmation of FIGO stage 3C or 4 ovarian cancer.
Radiological evidence of omental or peritoneal deposits that are accessible for radiology-guided biopsy.
At least one lesion on CT scan measuring at least 2 cm in maximum diameter performed in the past 31 days. Slightly older scans may be accepted at the discretion of the CI providing the results are considered to remain clinically relevant.
Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
Life expectancy of at least 6 months.
The patient is willing and able to provide written informed consent and comply with the protocol for the duration of the study, and scheduled visits and examinations.